This study is testing a drug called Dabogratinib (TYRA-300) in people with low grade upper tract urothelial carcinoma (a type of bladder cancer that affects the upper urinary tract). Researchers want to see how well Dabogratinib works and if it is safe. You might be able to join if you are at least 18 years old, have confirmed low-risk low grade upper tract urothelial carcinoma, and have a specific genetic marker called FGFR. The study aims to see what percentage of participants have their cancer completely disappear within 6 months of starting treatment. The current recruitment status is unclear, and the study plans to enroll 230 participants.

Study design

This is a Phase 2A/B, multi-center, open-label study, meaning both you and your doctors will know which dose of Dabogratinib you are receiving. It plans to enroll 230 participants.

What's involved

You would take Dabogratinib (TYRA-300) as an oral tablet daily, at either a 60mg or 80mg dose, or a dose that will be determined later. You will also need to provide tissue and urine samples for genetic testing.

Compensation

Not stated in the trial record.

Follow-up

The primary goal is measured within 6 months, but the total follow-up duration is not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.